Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)

Recruiting Phase 3 Interventional Study
Myopia
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
3 – 17
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
234 (estimated)
Sponsor
Ocus Innovation Ireland Limited · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Myopia, or shortsightedness, is a multifactorial disorder, governed by environmental and genetic factors. Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades and affecting the quality of life and economic health of individuals worsening socio-economic problems. Progressive myopia is nearly exclusively a condition of childhood and adolescenc…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Males and females, aged from 3 to less than 18 years. * Subjects showing myopia with a spherical equivalent refraction of both eyes at least -0.75 D at baseline. * The intraocular pressure in each eye must be equal or less than 21 mmHg. * The parents or the legal representativ…
Contacts

Irisi Sukaj

+355 68 90 37 854

isukaj@cvbf.net

CONTACT

Alessandra Foietta

+39 0382 1475411

afoietta@cvbf.net

CONTACT